Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials

BMC Ophthalmology
Chu Luan NguyenMichael Chilov

Abstract

To evaluate the relative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular age-related macular degeneration (AMD). Systematic literature review identifying RCTs comparing anti-VEGF agents to another treatment published before June 2016. Efficacy assessed by mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline at up to 2 years followup. Safety assessed by proportions of patients with death, arteriothrombotic and venous thrombotic events, and at least one serious systemic adverse event at up to 2 years of followup. Fifteen RCTs selected for meta-analysis (8320 patients). Two trials compared pegaptanib, and three trials compared ranibizumab versus control. Eight trials compared bevacizumab with ranibizumab. Two trials compared aflibercept with ranibizumab. There were no significant differences between bevacizumab and ranibizumab for BCVA at 1 or 2 years (weighted mean difference = - 0.57, 95% CI - 1.55 to 0.41, P = 0.25 and weighted mean difference = - 0.76, 95% CI - 2.25 to 0.73, P = 0.32, respectively). Ranibizumab was more effective in reducing CMT at 1 year (weighted mean difference = 4.49, 95% CI 1.13 to 7.84, P = ...Continue Reading

References

Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Apr 14, 2004·Archives of Ophthalmology·David S FriedmanUNKNOWN Eye Diseases Prevalence Research Group
Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Mar 22, 2008·The British Journal of Ophthalmology·M W Stewart, P J Rosenfeld
Jun 12, 2010·BMJ : British Medical Journal·Adnan TufailUNKNOWN ABC Trial Investigators
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe
May 5, 2012·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupFrederick L Ferris
Oct 23, 2012·Ophthalmology·Jeffrey S HeierUNKNOWN VIEW 1 and VIEW 2 Study Groups
Sep 9, 2015·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Salman SarwarQuan Dong Nguyen
May 10, 2016·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupStuart L Fine
Feb 13, 2018·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Joel HanhartShlomo Vinker

❮ Previous
Next ❯

Citations

May 2, 2019·EMBO Molecular Medicine·Anne Wolf, Thomas Langmann
Sep 26, 2019·Communications Biology·Sayan GhoshDebasish Sinha
Aug 21, 2020·Translational Vision Science & Technology·Maximilian G O GräfeJohannes F de Boer
Feb 8, 2020·Indian Journal of Pharmacology·Vinu JoseInderjeet Singh
Oct 14, 2020·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Marco PellegriniGiuseppe Giannaccare
Oct 16, 2020·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Martijn S VisserJ J V Busschbach
Jan 12, 2020·Communications Biology·Sayan GhoshDebasish Sinha
May 1, 2021·Klinische Monatsblätter für Augenheilkunde·Andrea R Wenkstern, Christophe Valmaggia
Aug 31, 2021·Biomedical Optics Express·Alice R MotschiChristoph K Hitzenberger

❮ Previous
Next ❯

Software Mentioned

ANCHOR
Review Manager
RevMan
MARINA
Ovid
Review Manager (

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.